Perspective Therapeutics (NYSE:CATX) Shares Gap Up to $12.28

Perspective Therapeutics, Inc. (NYSE:CATX) gapped up before the market opened on Wednesday . The stock had previously closed at $12.28, but opened at $12.80. Perspective Therapeutics shares last traded at $12.31, with a volume of 55,538 shares traded.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada decreased their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Oppenheimer decreased their price objective on Perspective Therapeutics from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th. Bank of America assumed coverage on Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective for the company. Finally, Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $21.00 price target for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $20.00.

Perspective Therapeutics Stock Up 3.2 %

The firm’s fifty day moving average price is $13.80.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The business had revenue of $0.53 million during the quarter. Research analysts anticipate that Perspective Therapeutics, Inc. will post -0.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Sykon Capital LLC grew its position in Perspective Therapeutics by 4.7% during the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock worth $378,000 after purchasing an additional 1,717 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics in the second quarter worth about $117,000. Point72 DIFC Ltd acquired a new stake in Perspective Therapeutics during the second quarter worth about $118,000. The Manufacturers Life Insurance Company purchased a new position in Perspective Therapeutics during the second quarter valued at approximately $188,000. Finally, ZWJ Investment Counsel Inc. acquired a new position in Perspective Therapeutics in the first quarter valued at approximately $26,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.